Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity
NCT ID: NCT07001904
Last Updated: 2025-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2023-11-01
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis
NCT03526705
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
NCT06050330
Levels of Pigment Epithelium-derived Factor in Patients With Psoriasis.
NCT05252741
Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis
NCT03469219
A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis
NCT02274363
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Interleukin (IL)-6 is a pleiotropic cytokine that regulates immunity, hematopoiesis, and inflammation. It is produced by keratinocytes, endothelial cells, fibroblasts, and immune cells like macrophages and dendritic cells. Increased IL-6 expression has been observed in psoriatic lesions, suggesting its involvement in disease pathogenesis
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients group
Patients with plaque psoriasis.
Enzyme-linked immunosorbent assay (ELISA)
The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum
Control group
Sex- and age-matched healthy control individuals.
Enzyme-linked immunosorbent assay (ELISA)
The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enzyme-linked immunosorbent assay (ELISA)
The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Patients clinically diagnosed with plaque psoriasis.
Exclusion Criteria
* Patients with other types of psoriasis.
* Those currently receiving systemic treatment.
* Individuals with other inflammatory diseases.
* Pregnant or lactating women.
* Those using contraceptive pills.
* Patients with metabolic conditions like diabetes mellitus or thyroid disorders.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adel Jamal Khaled Jadallah
Resident of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El-Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36264MS308/9/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.